

Hikma Algeria Factsheet

hikma.

June 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Algeria, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 30 years.



Local expertise, global strength



5

Manufacturing plants



860+

Employees



1

R&D centre

Hikma in Algeria is **ranked #3** among the pharmaceutical companies based on sales¹

Hikma has a **6% market share** of the total Algerian pharmaceutical market¹

Hikma was **the 1st** to establish an oral **oncology manufacturing plant** in Algeria

Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

Manufacturing high-quality medicines

General formulation plant

Manufactures a variety of medicines in various dosage forms producing approximately 40 million units/year

Penicillin plant

Manufactures approximately 20 million units/year of penicillin-based antibiotics

Cephalosporin plant

Produces approximately 10 million units/year of high-quality anti-infectives commonly used to treat bacterial infections

Oncology plant

First local oral oncology plant with the ability to produce various forms of oral oncology medicines

Injectables plant

Manufactures a variety of injectable medicines

A diversified portfolio of medicines

We offer the Algerian patient over 114 medicines covering 8 therapeutic areas to address a wide range of healthcare needs:



Anti-infectives



Oncology



Respiratory



Cardiovascular



Diabetes



Gastrointestinal



Dermatology



Central Nervous System

Hikma was **the 1st** multinational pharmaceutical company to register a **locally manufactured product** in Algeria

Hikma is **one of the leading providers** of oral-systemic, oral anti-infectives

Launching an average of **5 new products** in the market annually

Reference:

¹ Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period: MAT Apr. 2025. Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, T1G, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Company information

Vice President - North Africa Territory:
Eyad Abuawad

General Manager Algeria:
Abdelkrim Kabeche

Hikma Pharmaceuticals - Algeria

15,16 Zone d'activité Staoueli
Algiers - Algeria

Contacts

See www.hikma.com for contact forms